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Abstract
Background: p27Kip1 plays a major role as a negative regulator of the cell cycle. The regulation of
p27Kip1 degradation is mediated by its specific ubiquitin ligase subunits S-phase kinase protein (Skp)
2 and cyclin-dependent kinase subunit (Cks) 1. However, little is known regarding the prognostic
utility of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma.
Methods: Immunohistochemistry was performed for p27Kip1, Skp2 and Cks1 in tissue microarrays
of 482 renal cell carcinomas with follow-up. The data were correlated with clinicopathological
features. The univariate and multivariate survival analyses were also performed to determine their
prognostic significance.
Results: Immunoreactivity of p27Kip1, Skp2 and Cks1 was noted in 357, 71 and 82 patients,
respectively. Skp2 and Cks1 expression were not noted in chromophobe cancers. A strong
correlation was found between Skp2 and Cks1 expression (P < 0.001), both of which were
inversely related to p27Kip1 levels (P = 0.006 and P < 0.001), especially in primary and clear-cell
cancers. Low p27Kip1 expression and Skp2 expression were correlated with larger tumor size and
higher stage, as well as tumor necrosis. Cks1 expression was only correlated with tumor size. In
univariate analysis, low p27Kip1 expression, Skp2 and Cks1 expression were all associated with a
poor prognosis, while in multivariate analysis, only low p27Kip1 expression were independent
prognostic factors for both cancer specific survival and recurrence-free survival in patients with
RCC.
Conclusion: Our results suggest that immunohistochemical expression levels of p27Kip1, Skp2 and
Cks1 may serve as markers with prognostic value in renal cell carcinoma.
Background
Renal cell carcinoma (RCC) is the most common malig-
nancy in adult kidney, with 30,000 new cases per year in
the U.S. and 20,000 cases in the European Union [1].
Over the last 20 years, the incidence of renal cell carci-
noma in the two regions has increased by 30% [2].
Though the number of RCC cases in Asian is still
unknown, publications in this regard have suggested a
tendency of annual increase. In light of this situation, pre-
dicting the prognosis of RCC patients becomes essential
for planning and optimizing treatment strategies. The
prognosis of RCC is usually affected by such factors as per-
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formance status, pathological stage, tumor size, nuclear
grading, and microscopic tumor necrosis. Yet, the accu-
racy of the traditional clinical and histologic markers is
still unsatisfactory in certain clinical settings. There lies
the possibility that biologic markers, which have associ-
ated with tumor progression, could serve as accurate prog-
nostic markers or targets for specific intervention.
As the alteration of cell cycle is a hallmark of cancer, pro-
teins that are intimately involved in cell cycle regulation
are of particular interest. The cell cycle progression is
largely dependent on cyclins and cyclin-dependent
kinases (Cdks) [3]. Cdks are regulated by Cdk inhibitors,
including the INK4 family and the Cip/Kip family. The
p27, a member of the latter (p27/Kip1), negatively regu-
lates cell cycle by inactivating cyclin-CDK complex and
preventing the transition from G1 to S phase. The degra-
dation of p27 stimulates the activity of Cdk2/cyclin E and
Cdk2/cyclin A to promote cell proliferation. Recent evi-
dence also suggests that p27Kip1 is a putative tumor sup-
pressor, thus the loss of p27Kip1  may lead to the
uncontrolled proliferation of malignant cells [4].
Recently, reduced expression of p27Kip1 protein has been
proved to be highly associated with tumor progression
and poor prognosis in various malignant diseases [5].
However, downregulation of p27Kip1  mRNA is rarely
observed in human cancers [6]. Instead, the decrease in
p27Kip1  levels results mainly from ubiquitin-mediated
proteolysis, regulated by the F-box protein SKP2(S-phase
kinase-associated protein 2), and its cofactor, Cks1 [7].
SKP2 is an important component of the Skp1-Cullin-F-
box protein (SCF) complex, which functions as the main
rate-limiting regulator for the degradation of p27Kip1.
Hence, overexpression of Skp2 may lead to cell-cycle pro-
gression. Recent studies have also found that Skp2 may
modulate invasion of cancer cells independent of p27
degradation [8]. Cks1 is a member of the highly conserved
Cks/Suc1 proteins family, which confers an allosteric
change in Skp2 to increase its affinity to phosphorylated
p27Kip1 substrate [9,10]. Therefore, p27Kip1 degradation is
dependent upon the accumulation of Skp2 and Cks1 as
well as the rise in cyclin E. Recently, the expression levels
of p27Kip1, Skp2 and Cks1 were shown to be highly asso-
ciated with prognosis in a variety of cancers [10-13].
To date, very few studies have addressed the prognostic
role of P27Kip1and Skp2 in renal cell carcinoma. And no
study has elucidated the roles of Cks1 in RCCs. By using
tissue microarray, we therefore aimed at analyzing the
immunohistochemical expression patterns of p27Kip1,
Skp2, and Cks1 proteins, and their associations with clin-
ical and pathologic factors, as well as the prognostic
implications.
Methods
Patients and specimens
Our study cohort consisted of 482 patients who under-
went radical or partial nephrectomy for RCC at the Shan-
dong Provincial Hospital between 1993 and 2005. As
approved by the ethical committees of Shandong Provin-
cial Hospital, Formalin-fixed and paraffin-embedded
specimens of these cases were chosen for analysis. Clinical
data were recorded, including age, sex, and Eastern Coop-
erative Oncology Group (ECOG) performance status (PS)
score. Pathological variables were re-evaluated by 2
pathologists separately, including pT stage, Fuhrman
grade and histological subtype. Patients were staged
according to the 1997 staging system of the Union Inter-
national Contre le Cancer (UICC) and American Joint
Committee on Cancer (AJCC) [14]. The histological sub-
types were stratified using Heidelberg classification [15]
and the nuclear grade of tumors was determined by e
Fuhrman grading scheme [16]. Performance status was
determined using the Eastern Cooperative Oncology
Group Performance Score (ECOG-PS) scale. The patients
consisted of 329 men and 153 women, aging 19 to 94
years old, with a mean age of 62.1. There were 384 con-
ventional, 81 papillary, and 17 chromophobe cases of
RCCs respectively. 45 patients had distant metastases (to
the lung in 12 patient, bone in 4 patients, the lymph
nodes in 14 patients, gastrointestinal tract in 7 patients,
soft tissue in 2 patients and adrenal gland in 6 patients) at
the time of surgery. 324 (67.2%) tumors were discovered
incidentally, 126 (26.1%) were locally symptomatic and
32 patients (6.6%) had systemic disease symptoms. The
median period of follow-up for all patients was 62
months, ranging from 13 to 185 months.
Construction of tissue microarray blocks and 
immunohistochemistry
For immunohistochemical evaluation, tissue microarrays
were constructed using a manual tissue arrayer with acces-
sory (Beecher, Silver Spring, MD). 3 cylindrical core biop-
sies (0.6 mm in diameter) were taken from different sites
of each tumor and precisely arrayed in a recipient paraffin
tissue microarray block. 10 specimens of non-neoplastic
renal tissue resected from adjacent regions of renal cell
carcinoma were also analysed for comparison.
The procedures of immunohistochemical studies were
performed as described previously [13]. In brief, 4-mm
tissue microarray sections were incubated with the mouse
monoclonal antibodies targeting Skp2 (1:100, Zymed),
Cks1 (1:250, Zymed), p27Kip1 (1:50, Santa Cruz), using an
automated immunostainer(Leica AutoStainer XL,). Bind-
ing of the primary antibody was assessed using the DAKO
EnVision kit (DAKO Corp.), and the hematoxylin served
as counterstain. Incubation without the primary antibody
was used as a negative control.Journal of Experimental & Clinical Cancer Research 2008, 27:51 http://www.jeccr.com/content/27/1/51
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Assessment of immunohistochemical staining
Two pathologists, blinded to the clinicopathological data
and patients' outcomes, independently evaluated immu-
noreactivity of the tissue microarray slides. Discrepancies
were resolved by simultaneous re-examination of the
slides by both investigators. Immunostaining was evalu-
ated by recording the percentage of cells staining and scor-
ing the area of maximum staining on a 4-point scale, with
0 representing no staining and 3 representing the highest
staining. The results from 3 cores in the same patient were
averaged to obtain a mean value for subsequent statistical
analysis. According to the median percentage of positive
cells for each antibody, the protein expression results were
classified into 3 groups: Negative group; Low group (less
than the median value) and High group (greater than the
median value). The median values were: 40% for p27,
10% for Skp2, and 20% for Cks1. As described in previous
studies [13], the expressions of Skp2 and Cks1 was further
stratified as either positive or negative (Low+High group
versus Negative group), while the p27Kip1 expression was
further classified as high expression (High group) and low
expression (Negative+Low group).
Statistical analysis
Statistical data analyses were performed using SPSS 11.0
statistical software package (SPSS Inc., Chicago, IL). First,
the associations among Skp2, Cks1, p27Kip1 and clinico-
pathological factors were explored using χ2 test or Fisher's
exact test as appropriate. Correlations between variables
were tested according to the Spearman correlation test.
Recurrence-free survival (RFS) and cancer-specific survival
(CSS) were analyzed by Kaplan-Meier curves. The prog-
nostic role of different parameters in the disease recur-
rence and patient death was analyzed with the log-rank
test. For multivariate testing, a stepwise forward Cox's pro-
portional hazards regression model was performed to
define the risk factors for tumor recurrence and patient
death. P values less than 0.05 were considered significant.
Two-sided tests were used throughout all the analyses.
Results
Immunohistochemical expression and its correlation with 
clinicopathological variables
Representative examples of reactivity for p27Kip1, Skp2,
and Cks1 are shown in Figure 1.
In nonneoplastic renal tissue, the distal tubules, glomeru-
lar epithelial cells, and pelvic urothelium showed strong
nuclear p27Kip1 immunoreactivity but lacked immunore-
activity for Skp2 and Cks1.
The protein expression and clinicopathological data of the
patients are summarized in Table 1. As shown in Table 1,
Skp2, Cks1, and p27Kip1 expressions were not associated
with patients' age or gender, as well as the ECOG-PS. In
addition, none of the protein expression was associated
with the grade.
P27Kip1 expression was noted in 357 cases (74%), and
high expression of p27Kip1 was identified in 168 cases
(37%). The expression of p27Kip1 was significantly higher
in clear-cell RCC compared with other histological types
(P = 0.008). Furthermore, the expression significantly
decreased with increasing tumor stage (P = 0.002) and
tumor size (P < 0.001). In addition, the p27Kip1 was also
significantly downregulated in cases with tumor necrosis
(P = 0.001). And the expression was not significantly dif-
ferent between primary and metastatic tumors (P =
0.062).
Skp2 expression was noted in 68 of 384 (18%) clear cell
and 3 of 81 (4%) papillary tumors, but none of chromo-
phobe tumors. Skp2 expression was significantly corre-
lated with tumor stage (P < 0.001) and tumor size (P <
0.001), as well as tumor necrosis (P = 0.001). But Skp2
expression was not significantly different between pri-
mary and metastatic tumors (P = 0.136).
Cks1 expression was similar to Skp2, noted only in 82 of
384 (21%) clear cell and 8 of 81(10%) papillary tumors.
Among various clinicopathological variables, the expres-
sion of Cks1 was only correlated with tumor size (P =
0.018).
Associations among P27Kip1, Skp2 and Cks1 protein 
expression
A strong correlation was found between Skp2 and Cks1
expression (P < 0.001), both of which were inversely
related to p27Kip1 levels (P = 0.006 and P < 0.001). A fur-
ther test was performed between patients with different
metastatic status and histologic types. In primary RCCs,
relation between Skp2 and Cks1 expression and their
inverse relations to p27Kip1 levels are statistically signifi-
cant (P < 0.001, P = 0.001 and P = 0.001, respectively). But
in metastatic RCCs, no correlation was found: 5 Skp2-pos-
itive RCCs showed Cks1 positive expression, while 5
Skp2-positive and 10 Cks1-positive RCCs showed low
p27 expression, with a P value of 0.058, 0.179 and 0.893,
respectively.
In clear-cell RCCs, the correlation among the protein
expression was the same as that in the whole patients. But
in papillary tumors, only the inverse associations between
p27Kip1 and Cks1 was statistically significant (P = 0.027).
Survival analysis
At the end of follow-up, 131 patients died due to cancer
progression, 36 patients died of unrelated causes, and 128
patients developed disease recurrence.Journal of Experimental & Clinical Cancer Research 2008, 27:51 http://www.jeccr.com/content/27/1/51
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Expression of p27Kip1, Skp2 and Cks1 Figure 1
Expression of p27Kip1, Skp2 and Cks1. The proteins showing null/low or high levels of expression with nuclear pattern. 
(immunohistochemical staining; original magnification ×200; scale bar, 200 μm).Journal of Experimental & Clinical Cancer Research 2008, 27:51 http://www.jeccr.com/content/27/1/51
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In the univariate analysis, the Kaplan-Meier survival
curves showed that high Skp2 and Cks1 expression and
low p27Kip1 expression related to a poor survival with sta-
tistical significance, regardless of endpoints (Table 2, Fig.
2). The Cox's proportional hazards regression model
proved that tumor stage, tumor size and low p27Kip1
expression or lack of p27Kip1 immunoreactivity were inde-
pendent prognostic factors for different endpoints in
patients with RCC (Table 2).
Discussion
To our knowledge, the current study presents the largest
samples for investigating the expression of p27Kip1 and its
interacting cell cycle regulators: Skp2 and Cks1. This is
also the first article to analyse Cks1 expression in renal cell
carcinoma, with respect to possible associations with clin-
icopathological data as well as patients' prognosis. Fur-
thermore, for the first time, the possible relation between
levels of p27Kip1 and of its specific ubiquitin ligase subunit
Skp2 and Cks1 was assessed in renal cell carcinoma.
p27Kip1 is a member of the Cip/Kip family of CDK inhibi-
tory proteins and serves as an important regulator for both
cellular proliferation and tissue differentiation. Till now,
the significant association between low p27Kip1 expression
and adverse pathologic features or poor survival has been
found in patients with a variety of neoplasms, including
carcinoma of the gastrointestinal system [17], prostate
[18,19], breast [11], and lung [12]. However, previous
studies on p27Kip1 expression in RCCs presented contra-
dictory results. The low p27Kip1 expression was found to
be related to high-stage and high-grade RCCs by Langner
C et al. [13] and Hedberg et al. [20]. Yet, other studies
reported that the p27Kip1 level only was only related to the
TNM stage [21] or no associations at all [22]. Further-
more, although Hedberg et al. [20] reported the different
Table 1: Expression of p27Kip1, Skp2, and Cks1 in relation to clinicopathological parameters
P27 Skp2 Cks1
Variables No. Low High p-value N P p-value N P p-value
Age, years
Mean 62.5 61.3 0.904 62.0 65.1 0.723 60.0 62.3 0.630
Gender
Men 329 213 116 281 48 272 57
Women 153 101 52 0.785 130 23 0.898 120 33 0.266
Metastasis
Negative 437 279 158 376 61 359 78
Positive 45 35 10 0.062 35 10 0.136 33 12 0.148
Histology
Clear cell 384 239 145 316 68 302 82
Papillary 81 61 20 78 3 73 8
Chromophobe 17 14 3 0.008a 17 0 <0.001a 17 0 0.003a
pT stage
1 255 141 114 243 12 217 38
2 103 78 25 83 20 78 25
3+4 124 95 29 0.002b 85 39 <0.001b 97 27 0.304b
Tumor size
≤ 7.0 324 188 136 298 26 273 51
>7.0 158 126 32 <0.001 113 45 <0.001 119 39 0.018
Grade
17 8 4 6 3 2 6 8 1 0 6 0 1 8
2 250 159 91 215 35 201 49
3 121 86 35 102 19 103 18
43 3 2 3 1 0 0 . 0 7 5 c 26 7 0.361c 28 5 0.149c
Necrosis
Absent 432 271 161 376 56 352 80
Present 50 43 7 0.001 35 15 0.001 40 10 0.799
ECOG-PS
= 0 388 250 138 335 53 313 75
>0 94 64 30 0.505 76 18 0.178 79 15 0.452
Note: N indicates negative; P indicates positive;
a Histology, clear cell vs. others.
bStage, Stages I and II vs. Stages III and IV.
c Grade, Grade1/2 vs. Grade3/4.Journal of Experimental & Clinical Cancer Research 2008, 27:51 http://www.jeccr.com/content/27/1/51
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Kaplan-Meier survival curves according to protein expression of p27Kip1, Skp2 and Cks1 Figure 2
Kaplan-Meier survival curves according to protein expression of p27Kip1, Skp2 and Cks1. Cancer-specific survival of 
patients with RCC were significantly associated with the expression levels of p27Kip1 (A), Skp2(C), Cks1(E); Recurrence-free 
survival were significantly associated with the expression levels of p27Kip1 (B), Skp2(D), Cks1(F).Journal of Experimental & Clinical Cancer Research 2008, 27:51 http://www.jeccr.com/content/27/1/51
Page 7 of 8
(page number not for citation purposes)
p27Kip1 expression patterns among various histologic sub-
types, such results were not confirmed in other studies
[13]. In our study, the expression of p27Kip1 was signifi-
cantly higher in clear-cell RCC compared with other histo-
logic types and inversely related to TNM stage and tumor
size. And no association between p27Kip1 expression and
metastatic status confirms the result in previous study for
RCC [13] and other carcinomas [23].
More intriguingly, the controversy regarding association
between grade and p27Kip1 expression arised not only in
RCCs, but also in many other cancers [24,25]. This dis-
crepancy might be ascribed to the following reasons. First,
the assessment of the grade may be highly observer
dependent. Second, insufficient formalin fixation in some
specimens may result in artificial reduced labeling of
p27Kip1 in TMA. More likely, the root cause might stem
from the complex regulatory mechanisms of p27Kip1
abundance. For instance, a new ubiquitin ligase for
p27Kip1 has recently been identified, which is a member
for Skp2-independent down-regulation of p27Kip1 at the
G0–G1 transition [26].
The regulation of p27Kip1 is mainly determined by its rate
of degradation rather than by transcription or translation.
Recent studies indicate that Skp2 and Cks1, the cell-cycle
regulatory proteins, play essential roles in the degradation
of p27Kip1. Skp2 is an ubiquitin ligase responsible for tar-
geting P27Kip1 to the proteasome and Cks1 is an essential
cofactor for efficient Skp2 dependent p27Kip1 ubiquitina-
tion. Several studies have provided evidence that both the
Skp2 and Cks1 may have important roles in the develop-
ment of tumor aggressiveness and its expression may be
used as an independent prognostic factor for survival in
various carcinomas[12,13,17,27]. In this study, Skp2
expression was found to be significantly correlated with
advanced T stage, larger tumor size and necrosis, while
Cks1 only correlated with tumor size. The results imply
their importance in disease progression and confirm the
previous studies. However, the different expression pat-
tern among histologic types, such as no expression of
Skp2 and Cks1 in chromophobe RCC, has never been pre-
viously reported. Thus, the expression of Skp2 and Cks1
combined with p27Kip1  could help to separate the
chromophobe from the clear cell subtype.
As for the association among p27Kip1, Skp2 and Cks1, it is
still in dispute [10-13]. In this study, there was a signifi-
cant positive correlation between SKP2 and CKS1 expres-
sion, as well as an inverse relationship between p27Kip1
and the 2 proteins. To examine whether other factors
affected the association, we carried out further subanalysis
dividing patients into subgroups based upon histologic
subtypes and metastatic status. The correlation among
these proteins was only found to be significant in primary
and clear-cell RCCs. The observation may partially explain
the current dispute, as the different samples used by differ-
ent researchers. It also suggests that p27Kip1 downregula-
tion may involve several pathways and occur through
corresponding pathway in different status.
Consistent with previous studies [13,20-22], we found
that TNM stage and tumor size were strong predictive
prognostic markers in patients with RCC. With regard to
prognostic significance of protein expression, our study
also demonstrated that low p27Kip1 expression signifi-
cantly correlated with a poor outcome. Although the Skp2
and Cks1 expression correlated within inferior CSS and
DFS in our univariate analysis, it did not remain prognos-
tically independent in multivariate comparison.
Conclusion
In summary, our study suggests that immunohistochemi-
cal expression levels of p27Kip1, Skp2 and Cks1 may serve
as markers with prognostic implication. The inverse asso-
ciation between p27Kip1 and Skp2 or Cks1 indicates the
important roles of Skp2 and Cks1 in targeting the destruc-
tion of p27Kip1, and these regulatory proteins may well be
considered as novel targets of therapeutic intervention in
RCC in the future.
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